Subtype
Pharyngeal Neoplasm
CI-CAN-00001414Explore in graph →
Non-malignant421 active trials1 approved drugs2 evidence items
Loading cancer entity…
Subtype
CI-CAN-00001414Explore in graph →
Clinical trials
1,344 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00970502 | Erlotinib, Celecoxib and Reirradiation for Recurrent Head and Neck Cancer | completed | Phase 1 / Phase 2 | 15 | Johnny KaoOTHER | 1 | Apr 10, 2017 | clinicaltrials |
| NCT03047525 | Study of DC-CTL Combined With CIK for Advanced Solid Tumor | unknown | Phase 1 / Phase 2 | 200 | Xiaoyi HuangOTHER | 1 | Feb 9, 2017 | clinicaltrials |
| NCT00516087 |
| LMP1- and LMP2-Specific CTLs to Patients With EBV-Positive NPC (NATELLA)(NATELLA) |
| completed |
| Phase 1 |
| 23 |
| Baylor College of MedicineOTHER |
| 1 |
| Feb 7, 2017 |
| clinicaltrials |
| NCT02980315 | A New EBV Related Technologies of T Cells in Treating Malignant Tumors and Clinical Application | unknown | Phase 1 / Phase 2 | 20 | The Second Hospital of Nanjing Medical UniversityOTHER | 1 | Dec 2, 2016 | clinicaltrials |
| NCT01283178 | Phase I Study of IMRT and Molecular-Image Guided Adaptive Radiation Therapy for Advanced HNSCC | terminated | Phase 1 | 3 | Virginia Commonwealth UniversityOTHER | 1 | Oct 31, 2016 | clinicaltrials |
| NCT01921426 | A Phase 1 Dose Escalation Study of GC4419 in Combination With Chemoradiation for Squamous Cell Cancer of the Head & Neck | completed | Phase 1 | 30 | Galera Therapeutics, Inc.INDUSTRY | 1 | Sep 22, 2016 | clinicaltrials |
| NCT01528137 | Talactoferrin in Treating Patients With Relapsed or Refractory Non-Small Cell Lung Cancer or Squamous Cell Head and Neck Cancer | terminated | Phase 1 | 4 | Stanford UniversityOTHER | 1 | Aug 2, 2016 | clinicaltrials |
| NCT02334319 | Ganetespib Window of Opportunity Study in Head and Neck Cancers | terminated | Phase 1 | 3 | Emory UniversityOTHER | 1 | Jul 26, 2016 | clinicaltrials |
| NCT02523430 | HepaSphere Interventional Therapy Using Digital Subtraction Angiography(DSA) for Nasopharyngeal Carcinoma | completed | Phase 1 / Phase 2 | 60 | Fuda Cancer Hospital, GuangzhouOTHER | 1 | Jul 19, 2016 | clinicaltrials |
| NCT01108042 | TPF-Induction Chemotherapy of Oropharyngeal and Cavity of the Mouth Cancer | completed | Phase 1 / Phase 2 | 71 | Orlando Guntinas-Lichius, Prof. Dr. med.OTHER | 1 | May 18, 2016 | clinicaltrials |
| NCT02761291 | Study of Cytolytic Viral Activation Therapy (CVAT) for Recurrent/Metastatic Nasopharyngeal Carcinoma | unknown | Phase 1 | 18 | Chang Gung Memorial HospitalOTHER | 1 | May 16, 2016 | clinicaltrials |
| NCT00397384 | Erlotinib Hydrochloride and Cetuximab in Treating Patients With Advanced Gastrointestinal Cancer, Head and Neck Cancer, Non-Small Cell Lung Cancer, or Colorectal Cancer | completed | Phase 1 | 43 | National Cancer Institute (NCI)NIH | 1 | Sep 30, 2015 | clinicaltrials |
| NCT01586182 | Stereotactic Boost for Oropharyngeal Squamous Cell Carcinoma | withdrawn | Phase 1 / Phase 2 | 0 | Dana-Farber Cancer InstituteOTHER | 1 | Sep 4, 2015 | clinicaltrials |
| NCT00706316 | Administration of Epstein Barr Virus - Specific Cytotoxic T-Lymphocytes to Metastatic EBV-Positive Nasopharygneal Cancer(NPC-CTL) | completed | Phase 1 | 5 | University Health Network, TorontoOTHER | 1 | Jul 10, 2015 | clinicaltrials |
| NCT02058017 | OPB-51602 in Locally Advanced Nasopharyngeal Carcinoma Prior to Definitive Chemoradiotherapy | terminated | Phase 1 | 9 | National University Hospital, SingaporeOTHER | 1 | Jun 19, 2015 | clinicaltrials |
| NCT01334177 | TLR8 Agonist VTX-2337 and Cetuximab in Treating Patients With Locally Advanced, Recurrent, or Metastatic Squamous Cell Cancer of Head and Neck | completed | Phase 1 | 13 | University of WashingtonOTHER | 1 | Mar 5, 2015 | clinicaltrials |
| NCT01462903 | A Study of Adoptive Immunotherapy With Autologous Tumor Infiltrating Lymphocytes in Solid Tumors | unknown | Phase 1 | 20 | Sun Yat-sen UniversityOTHER | 1 | Nov 24, 2014 | clinicaltrials |
| NCT00101348 | Erlotinib and Cetuximab With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Kidney, Colorectal, Head and Neck, Pancreatic, or Non-Small Cell Lung Cancer | completed | Phase 1 / Phase 2 | 66 | National Cancer Institute (NCI)NIH | 1 | Jun 11, 2014 | clinicaltrials |
| NCT00049283 | Erlotinib, Docetaxel, and Radiation Therapy in Treating Patients With Locally Advanced Head and Neck Cancer | completed | Phase 1 | 30 | National Cancer Institute (NCI)NIH | 1 | Jun 6, 2014 | clinicaltrials |
| NCT01712919 | Chemoradiation Plus Weekly c225 Against Locoregionally Advanced Nasopharyngeal Carcinoma (NPC) | completed | Phase 1 / Phase 2 | 61 | Jiangsu Cancer Institute & HospitalOTHER | 1 | Mar 24, 2014 | clinicaltrials |
| NCT01735409 | Dose-finding Study of Abraxane in Combination With Cisplatin to Treat Advanced Nasopharyngeal Carcinoma(ABX-DDP-Dose) | unknown | Phase 1 / Phase 2 | 69 | Sun Yat-sen UniversityOTHER | 1 | Jan 28, 2014 | clinicaltrials |
| NCT01728480 | Entolimod in Treating Patients With Stage III-IV Squamous Cell Head and Neck Cancer Receiving Cisplatin and Radiation Therapy | withdrawn | Phase 1 | 0 | Roswell Park Cancer InstituteOTHER | 0 | Dec 11, 2013 | clinicaltrials |
| NCT00055770 | Erlotinib Plus Docetaxel in Treating Patients With Locally Advanced, Metastatic, or Recurrent Head and Neck Cancer | completed | Phase 1 / Phase 2 | 45 | National Cancer Institute (NCI)NIH | 1 | Nov 25, 2013 | clinicaltrials |
| NCT00031681 | 7-Hydroxystaurosporine and Irinotecan Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Triple Negative Breast Cancer (Currently Accruing Only Triple-negative Breast Cancer Patients Since 6/8/2007) | completed | Phase 1 | 41 | National Cancer Institute (NCI)NIH | 1 | Sep 30, 2013 | clinicaltrials |
| NCT00049166 | Erlotinib and Radiation Therapy With or Without Cisplatin in Treating Patients With Mouth or Throat Cancer | completed | Phase 1 | 48 | National Cancer Institute (NCI)NIH | 1 | Sep 30, 2013 | clinicaltrials |
| NCT00006106 | ONYX-015 With Cisplatin and Fluorouracil in Treating Patients With Advanced Head and Neck Cancer | withdrawn | Phase 1 | 0 | National Cancer Institute (NCI)NIH | 1 | Jul 10, 2013 | clinicaltrials |
| NCT00906360 | Sunitinib, Cetuximab, and Radiation Therapy in Treating Patients With Locally Advanced or Recurrent Squamous Cell Carcinoma of the Head and Neck | terminated | Phase 1 | 36 | National Cancer Institute (NCI)NIH | 1 | Jul 2, 2013 | clinicaltrials |
| NCT00101270 | Oxaliplatin and Irinotecan in Treating Young Patients With Refractory Solid Tumors or Lymphomas | completed | Phase 1 | 24 | National Cancer Institute (NCI)NIH | 1 | Jun 5, 2013 | clinicaltrials |
| NCT00089362 | Alvespimycin Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors | completed | Phase 1 | 30 | National Cancer Institute (NCI)NIH | 1 | Apr 10, 2013 | clinicaltrials |
| NCT00004074 | Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu | completed | Phase 1 | 15 | National Cancer Institute (NCI)NIH | 1 | Feb 28, 2013 | clinicaltrials |
| NCT00023959 | Bevacizumab, Fluorouracil, and Hydroxyurea Plus Radiation Therapy in Treating Patients With Advanced Head and Neck Cancer | completed | Phase 1 | 39 | National Cancer Institute (NCI)NIH | 1 | Feb 7, 2013 | clinicaltrials |
| NCT00033449 | Gefitinib and Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III or Stage IV Head and Neck Cancer | terminated | Phase 1 | 30 | National Cancer Institute (NCI)NIH | 1 | Jan 25, 2013 | clinicaltrials |
| NCT00081211 | Intratumoral PV701 in Treating Patients With Advanced or Recurrent Unresectable Squamous Cell Carcinoma of the Head and Neck | terminated | Phase 1 | 30 | National Cancer Institute (NCI)NIH | 1 | Jan 24, 2013 | clinicaltrials |
| NCT00064103 | Gene Therapy in Preventing Cancer in Patients With Premalignant Carcinoma of the Oral Cavity or Pharynx | completed | Phase 1 / Phase 2 | 51 | National Cancer Institute (NCI)NIH | 1 | Jan 23, 2013 | clinicaltrials |
| NCT00030498 | Erlotinib in Treating Patients With Solid Tumors and Liver or Kidney Dysfunction | completed | Phase 1 | 75 | National Cancer Institute (NCI)NIH | 1 | Jan 16, 2013 | clinicaltrials |
| NCT00063895 | Erlotinib in Treating Patients With Advanced Non-Small Cell Lung Cancer, Ovarian Cancer, or Squamous Cell Carcinoma of the Head and Neck | completed | Phase 1 / Phase 2 | 80 | National Cancer Institute (NCI)NIH | 1 | Jan 9, 2013 | clinicaltrials |
| NCT00078546 | EBV-Specific CTLs Following CD45 Antibody to Patients With Epstein-Barr Virus (EBV) + Nasopharyngeal Carcinoma (NPC)(CLANC) | completed | Phase 1 | 12 | Baylor College of MedicineOTHER | 1 | Jul 30, 2012 | clinicaltrials |
| NCT01637194 | Cetuximab and Everolimus in Treating Patients With Metastatic or Recurrent Colon Cancer or Head and Neck Cancer | completed | Phase 1 | 12 | Fox Chase Cancer CenterOTHER | 1 | Jul 11, 2012 | clinicaltrials |
| NCT00396617 | Voice Prosthesis Made in Porous Titanium After Total Laryngectomy or Pharyngolaryngectomy | unknown | Phase 1 | 14 | University Hospital, Strasbourg, FranceOTHER | 1 | Jul 2, 2012 | clinicaltrials |
| NCT00515957 | Study of LMP1- and LMP2- Specific Cytotoxic T-Lymphocytes (CTL)(DELLA) | withdrawn | Phase 1 | 0 | Baylor College of MedicineOTHER | 0 | Apr 16, 2012 | clinicaltrials |
| NCT00212108 | A Study Of Nasopharyngeal Carcinoma (NPC) Treated With Celecoxib And ZD1839 | completed | Phase 1 / Phase 2 | 22 | National University Hospital, SingaporeOTHER | 1 | Apr 2, 2012 | clinicaltrials |
| NCT01256853 | Modified Vaccinia Ankara (MVA) Vaccine Study | completed | Phase 1 | 18 | Chinese University of Hong KongOTHER | 1 | Dec 22, 2011 | clinicaltrials |
| NCT01449942 | Clinical Study of EBV-LMP1 Targeted DNAzyme to Treat Nasopharyngeal Carcinoma(NPC-DZ) | completed | Phase 1 / Phase 2 | 40 | Xiangya Hospital of Central South UniversityOTHER | 1 | Oct 10, 2011 | clinicaltrials |
| NCT00123864 | Study Using Intensity-modulated Radiation Therapy in Patients With Nasopharynx Cancer to Permit Sparing of Contralateral Parotid Gland Function | completed | Phase 1 / Phase 2 | 25 | Alberta Health servicesOTHER | 1 | Feb 9, 2010 | clinicaltrials |
| NCT00078494 | Peptide Vaccine to Prevent Recurrence of Nasopharyngeal Cancer | completed | Phase 1 | 99 | National Institutes of Health Clinical Center (CC)NIH | 1 | Mar 4, 2008 | clinicaltrials |
| NCT00080028 | Motexafin Gadolinium With Chemotherapy and Radiation Therapy for the Treatment of Advanced Head and Neck Cancer | terminated | Phase 1 | 18 | Pharmacyclics LLC.INDUSTRY | 1 | May 8, 2007 | clinicaltrials |
Data updated 23 days agoSource updated Apr 10, 2017source: clinicaltrials